Highlights • Family history of prostate cancer is an important risk factor of being diagnosed with the disease, even in the setting of low PSA. • Black men are at…
Highlights • Randomized trials show PSA screening decreases prostate cancer-mortality. • Adjunct tests and focus on high-risk patients will improve prostate cancer screening. • A closer look at divergence in…
Abstract Prostate cancer (PCa) screening has evolved beyond PSA and digital rectal exam to include multiparametric prostate MRI (mpMRI). Incorporating this advanced imaging tool has further limited the well-established problem…
Highlights • Prostate specific antigen is a proven screening test that has reduced prostate cancer mortality. • A desire to improve the positive and negative predictive values of PSA has…
Highlights • There is still uncertainty about PI-RADS 3 lesions. • Machine learning (ML) models are effective in biopsy decision making in PI-RADS 3 lesions. • Parameters such as SII,…
Highlights • GGT for patients with PCa increased from 21 in Q2 2015 to 1,509 in Q3 2020. • Proportion of GGT ordered by urologists increased from 0% in 2015…
Highlights • Our study explores the efficacy of prostate ablation, both whole-gland and partial-gland ablation, as an emerging treatment for localized prostate cancer, emphasizing its potential in reducing quality of…
Highlights • Significant correlation between HbA1c and prostate cancer mortality not incidence. • 26% and 21% increase in the risk of CSM and ACM for each 1% increase in HbA1c….
Highlights • Observational studies suggest favorable associations between statin use and prostate cancer (CaP) outcomes, data from randomized-controlled trials remain inconclusive. • We explored the relationship between statin use and…
Highlights • Among individuals undergoing targeted biopsy of PI-RADS 5 lesions on prostate MRI, 15.2% were found to have Gleason Grade Group 1 prostate cancer. • The majority of those…
